News - Page 5 of 40

“Anti-CCR4 monoclonal antibody enhances antitumor immunity by modulating tumor-infiltrating Tregs in an ovarian cancer xenograft humanized mouse model.”

Chang, D. K., E. Peterson, J. Sun, C. Goudie, R. I. Drapkin, J. F. Liu, U. Matulonis, Q. Zhu and W. A. Marasco
Oncoimmunology, 2016.

“A Division of Labor between YAP and TAZ in Non-Small Cell Lung Cancer.”

Shreberk-Shaked, M., B. Dassa, S. Sinha, S. Di Agostino, I. Azuri, S. Mukherjee, Y. Aylon, G. Blandino, E. Ruppin and M. Oren
Cancer Res, 2020.

“PD-L1 recruits phospholipase C and enhances tumorigenicity of lung tumors harboring mutant forms of EGFR.”

Ghosh, S., N. B. Nataraj, A. Noronha, S. Patkar, A. Sekar, S. Mukherjee, S. Winograd-Katz, L. Kramarski, A. Verma, M. Lindzen, D. D. Garcia, J. Green, G. Eisenberg, H. Gil-Henn, A. Basu, Y. Lender, S. Weiss, M. Oren, M. Lotem, B. Geiger, E. Ruppin and Y. Yarden
Cell Rep, 2021.

“TP53 missense mutations in PDAC are associated with enhanced fibrosis and an immunosuppressive microenvironment.”

Maddalena, M., G. Mallel, N. B. Nataraj, M. Shreberk-Shaked, O. Hassin, S. Mukherjee, S. Arandkar, R. Rotkopf, A. Kapsack, G. Lambiase, B. Pellegrino, E. Ben-Isaac, O. Golani, Y. Addadi, E. Hajaj, R. Eilam, R. Straussman, Y. Yarden, M. Lotem and M. Oren
Proc Natl Acad Sci U S A, 2021.

“Excess of the NF-kB p50 subunit generated by the ubiquitin ligase KPC1 suppresses tumors via PD-L1- and chemokines-mediated mechanisms.”

Kravtsova-Ivantsiv, Y., G. Goldhirsh, A. Ivantsiv, O. Ben Itzhak, Y. T. Kwon, E. Pikarsky and A. Ciechanover
Proc Natl Acad Sci U S A, 2020.

“Targeting HER3, a Catalytically Defective Receptor Tyrosine Kinase, Prevents Resistance of Lung Cancer to a Third-Generation EGFR Kinase Inhibitor.”

Romaniello, D., I. Marrocco, N. Belugali Nataraj, I. Ferrer, D. Drago-Garcia, I. Vaknin, R. Oren, M. Lindzen, S. Ghosh, M. Kreitman, J. C. Kittel, N. Gaborit, G. Bergado Baez, B. Sanchez, R. Eilam, E. Pikarsky, L. Paz-Ares and Y. Yarden
Cancers (Basel), 2020.

“Phosphoproteomics reveals novel modes of function and inter-relationships among PIKKs in response to genotoxic stress.”

Schlam-Babayov, S., A. Bensimon, M. Harel, T. Geiger, R. Aebersold, Y. Ziv and Y. Shiloh
EMBO J, 2020.

“The cerebellar degeneration in ataxia-telangiectasia: A case for genome instability.”

Shiloh, Y.
DNA Repair (Amst), 2020.

“Are we ready for targeted therapy combinations in HCC?”

Cinnamon, E. and E. Pikarsky
Gut, 2020.

“Modulation of the cell cycle regulating transcription factor E2F1 pathway by the proteasome following amino acid starvation.”

Fabre, B., I. Livneh, T. Ziv and A. Ciechanover
Biochem Biophys Res Commun, 2019.

“Inhibition of a pancreatic cancer model by cooperative pairs of clinically approved and experimental antibodies.”

Maron, R., B. Schechter, N. B. Nataraj, S. Ghosh, D. Romaniello, I. Marrocco, A. Noronha, S. Carvalho, Y. Yarden and M. Sela
Biochem Biophys Res Commun, 2019.

“De novo macrocyclic peptides that specifically modulate Lys48-linked ubiquitin chains.”

Nawatha, M., J. M. Rogers, S. M. Bonn, I. Livneh, B. Lemma, S. M. Mali, G. B. Vamisetti, H. Sun, B. Bercovich, Y. Huang, A. Ciechanover, D. Fushman, H. Suga and A. Brik
Nat Chem, 2019.

“Diverse fate of ubiquitin chain moieties: The proximal is degraded with the target, and the distal protects the proximal from removal and recycles.”

Sun, H., S. M. Mali, S. K. Singh, R. Meledin, A. Brik, Y. T. Kwon, Y. Kravtsova-Ivantsiv, B. Bercovich and A. Ciechanover
Proc Natl Acad Sci U S A, 2019.

“Transcriptional profiling reveals a subset of human breast tumors that retain wt TP53 but display mutant p53-associated features.”

Benor, G., G. Fuks, S. F. Chin, O. M. Rueda, S. Mukherjee, S. Arandkar, Y. Aylon, C. Caldas, E. Domany and M. Oren
Mol Oncol, 2020.

“A Combination Of Approved Antibodies Overcomes Resistance Of Lung Cancer To Osimertinib By Blocking Bypass Pathways.”

Romaniello, D., L. Mazzeo, M. Mancini, I. Marrocco, A. Noronha, M. S. Kreitman, S. Srivastava, S. Ghosh, M. Lindzen, T. M. Salame, A. Onn, J. Bar and Y. Yarden
Clin Cancer Res, 2018.

“SILAC identifies LAD1 as a filamin-binding regulator of actin dynamics in response to EGF and a marker of aggressive breast tumors.”

Roth, L., S. Srivastava, M. Lindzen, A. Sas-Chen, M. Sheffer, M. Lauriola, Y. Enuka, A. Noronha, M. Mancini, S. Lavi, G. Tarcic, G. Pines, N. Nevo, O. Heyman, T. Ziv, O. M. Rueda, D. Gnocchi, E. Pikarsky, A. Admon, C. Caldas and Y. Yarden
Sci Signal, 2018.